犬细小病毒四川株的分离与鉴定

为更好地了解我国细小病毒流行情况,笔者从四川农大动物医院采集5份患出血性肠炎犬的粪便,通过猫肾细胞(F81)传代培养后,成功分离到两株犬细小病毒。对两株病毒进行病毒形态学、理化学、血凝试验、PCR鉴定与分子生物学系统鉴定后,证实分离株是犬细小病毒,通过VP2结构蛋白测序分析表明,新分离到的两株细小病毒抗原型分别属于CPV-2a和CPV-2b。     

犬细小病毒四川株的分离与鉴定

采集5份患出血性肠炎犬的粪便,通过猫肾细胞(F81)传代培养后,成功分离到2株病毒。对2株病毒进行病毒形态学、理化学、血凝试验、PCR鉴定与分子生物学系统鉴定后,证实分离株是犬细小病毒,通过VP2结构蛋白测序分析表明,新分离到的2株细小病毒抗原型分别属于CPV-2a和CPV-2b。     

犬细小病毒的分离与鉴定

<正> 犬细小病毒(CPV)是引起犬急性出血性胃肠炎和幼犬心肌炎的主要病原。1977年首次由Eugster和Nairn从患腹泻的病犬粪便中分离出病毒,随后许多国家陆续报道。1980年秋以来,在我国警犬中发生疑似本病的流行,对养犬业造成了极大的威胁,严重影响了我国警(军)犬事业的发展。1982年开始使用国外引进疫苗,但仍未控制流行。为查清病原,确定病性,以便提供有效地诊断和     

犬细小病毒TZ2#株的分离与鉴定

采集疑似犬细小病毒(CPV)感染犬的粪便,采用同步培养法接种胎猫肾细胞(FK81)进行病毒分离鉴定。通过PCR检测、HA试验、PEG纯化,获得1株犬细小病毒,并命名为TZ2#株。感染的F81细胞48h后出现明显的细胞病变;在感染的FK81细胞中扩增出CPV基因的特异性片段;病毒液可凝集猪红细胞,血凝价为1∶64,其血凝性能被特异性抗体抑制。     

犬细小病毒YZ分离株的鉴定

对1999年冬季江苏省实验动物Beagle犬基地暴发的以拉稀、便血、高死亡率的病犬作流行病学调查、病理和实验室诊断。粪便血凝价高达2^14以上，并用HI加以验证，初步诊断为犬细小病毒感染引起的出血性肠炎。用FK81细胞（胎猎肾传代细胞）分离病毒，细胞上清HA试验阳性；负染电镜观察到在小为20nm左右的病毒粒子；接种病料的细胞IFA检测可见特异性的亮绿色荧光。在小肠的病理切片中见到典型的嗜酸性核内包涵体。以此确诊为犬细小病毒感染引起的出血性肠炎。利用双琼脂空斑技术克隆一株犬细小病毒，命名为CPV－YZ株，其核酸型是单链DNA，对甲醛敏感，对氯仿、酸、胰蛋白酶不敏感，80℃ 60分钟失去活力，0．1ml TCID50是10^-6.8,SDS-PAGE电泳两条清晰的条带分别为：76kD的VP1，64kD的VP2。     

犬细小病毒的分离鉴定

用猫肾(F81)细胞从沈阳某养犬场病死犬的肠内容物中,分离到1株细小病毒.根据犬细小病毒(CPV)VP2基因的核苷酸序列设计合成了两对特异性引物,对分离的病毒株进行PCR扩增,分别得到846 bp和815 bp的2个片段,PCR产物经纯化后测序,测序结果与GenBank中已发表的CPV参考株PLI-IV(typeFPV)、CPV-b(type2)、V154(type2a)、LCPV-V204(type2b)、LCPV-V139(type2c(a))和LCPV-V203(type2c(b))的VP2基因序列相比较,根据分析比较的数据结果,确定此株细小病毒为CPV-2a亚型.     

犬细小病毒HZ0761株的分离与鉴定

采集疑似细小病毒(CPV)感染犬的粪便,采用同步培养法接种胎猫肾细胞(F81)进行病毒分离鉴定。通过PCR检测、HA试验、IFA鉴定、电镜观察和空斑纯化,获得1株犬细小病毒,并命名为HZ0761。感染的F81细胞48h后出现明显的细胞病变;在病料和感染的F81细胞中均扩增出CPV VP2基因的特异性片段(221 bp);病毒液可凝集猪红细胞,血凝价为1∶28,其血凝性能被特异性抗体抑制;IFA可见特异性亮绿色荧光;电镜观察感染的F81细胞核内可见20 nm左右的病毒颗粒;病毒液的TCID50为10-4.8/mL,VP2基因序列分析显示该毒株为CPV-2 a型。     

犬细小病毒DD株的分离鉴定和VP2基因序列分析

本实验室对从疑似犬细小病毒感染的发病犬分离的病毒采用同步培养法接种猫肾细胞（CRFK）增殖,通过PCR试验、IFA试验和VP2基因测序分析等方法进行鉴定并分型,获得一株犬细小病毒强毒株,命名为CPV-DD株。对分离病毒进行PCR扩增,可扩增出特异性DNA片段（1 163 bp）;盲传至第6代时,病毒液的HA效价为1∶1...     

犬细小病毒宁夏株的分离与鉴定

本试验采集宁夏地区疑似犬细小病毒感染病犬的粪便拭子,经过预处理后同步接种胎猫肾细胞(FK81),盲传3代后发现FK81细胞出现明显的细胞毒性改变(CPE)。冻融收获病毒后,对分离出来的病毒进行电镜观察、间接免疫荧光试验(IFA)检测、特异性PCR鉴定及VP2全基因序列扩增分析,成功分离培养出1株犬细小病毒(CPV)。     

犬细小病毒山东流行株分离鉴定及其全基因组测序分析

为了解山东地区犬细小病毒的流行及其变异情况,应用F81细胞从山东地区送检的发病犬粪便中分离出4株细小病毒,根据PCR和电镜技术对其进行鉴定,并对分离株的全基因组进行克隆测序与序列分析。结果表明:所分离到的4株病毒均能在F81细胞上产生明显的细胞病变,经PCR及电镜观察鉴定为犬细小病毒,分别命名为QN1/QN2/QN3/QN4株。全基因组分析结果显示,除QN3株的基因组全长为4 756 nt外,其余3株均为4 757 nt;4个分离株之间全序列核苷酸同源性为99.31%,与GenBank登录的10株具有代表性的CPV核苷酸序列比对,同源性为98.2%⁹9.9%;VP2基因的核苷酸序列同源性为98.5%99.9%;VP2基因的核苷酸序列同源性为98.5%⁹9.9%,氨基酸序列同源性为98.1%99.9%,氨基酸序列同源性为98.1%¹00%;表明各分离毒株的亲缘关系较近,同属于NewCPV-2a亚型。     

广东珠三角地区犬细小病毒分离与鉴定

为了解珠三角地区犬细小病毒(CPV)的流行情况及研制有效的疫苗,本研究开展了CPV流行病学调查,并将32份疑似CPV感染犬的粪便样品处理后接种F81细胞进行病毒分离,并对分离株进行鉴定。鉴定结果显示:32份样品中有19份样品提取液在F81细胞上可以产生明显的细胞病变;HA效价可达到1∶256。回归动物试验显示分离株可以导致犬出现明显的CPV感染症状,PCR鉴定也进一步确定所分离的病毒为CPV。通过VP2基因同源性分析显示分离株与国内主要的流行基因亚型CPV-2a的同源性达98%以上。     

Antibody levels and protection to canine parvovirus type 2

The relationship between maternally derived antibody (MDA) levels and protection to canine parvovirus (CPV) infection in pups is reported. Twelve pups with a wide range of haemagglutination inhibiting (HI) titres of MDA to CPV were divided into four groups, with each group balanced for antibody titres. The dogs were inoculated with a field CPV-2b strain and clinical signs, virus shedding and antibody response were assessed. The CPV was not detected in the faeces of dogs with HI titres of 320 at any time. In dogs with HI titres up to 160, active CPV replication after challenge was demonstrated by real-time polymerase chain reaction. The successful infection of dogs with HI titres of 80 and 160 was confirmed by seroconversion, evaluated at day 14 post-infection. These findings demonstrated that CPV infection could also occur in the presence of MDA HI titres (> or =80) usually considered fully protective.     

VP2 gene of a canine parvovirus isolate from stool of a puppy

VP2 gene of a canine parvovirus (CPV) isolate from the feces of a puppy which was diagnosed to be CPV infection was analysed. The result indicated that this clinical isolate was phylogenetically close to the isolate of wild-type CPV (strain CPV-T37) prevailing in Taiwan rather than isolates from Japan.     

貉细小病毒SD1607株的分离鉴定及VP 2基因序列分析

从疑似患细小病毒性肠炎的貉子肠道组织样品中分离到一株貉细小病毒(RDPV-SD1607)。为研究其分子遗传特征,对该分离株VP2基因进行克隆序列分析,结果显示,RDPV-SD1607的VP2序列与RDPV-HB3的相似性最高,为99.49%,属于CPV-2亚型;利用其核苷酸序列建立系统进化树发现,RDPV-SD1607处于犬细小病毒分支,且处于CPV-2亚型和CPV-2a亚型分支之间。结果表明,RDPV-SD1607株与犬细小具有共同的遗传起源,推测其可能正处于CPV-2亚型向CPV-2a亚型进化的中间状态,或是CPV适应貉而形成的新毒株。     

Three-year serologic immunity against canine parvovirus type 2 and canine adenovirus type 2 in dogs vaccinated with a canine combination vaccine

A group of client-owned dogs and a group of dogs at a commercial kennel were evaluated for duration of antibody responses against canine parvovirus type 2 (CPV-2) and canine adenovirus type 1 (CAV-1) after receiving a combination vaccine containing recombinant canarypox-vectored canine distemper virus (CDV) and modified-live CPV-2, CAV-2, and canine parainfluenza virus, with (C6) or without (C4) two serovars of Leptospira (Recombitek C4 or C6, Merial). Duration of antibody, which correlates with protective immunity, was found to be at least 36 months in both groups. Recombitek combination vaccines can confidently be given every 3 years with assurance of protection in immunocompetent dogs against CPV-2 and CAV-1 as well as CDV. This allows this combination vaccine, like other, similar modified- live virus combination products containing CDV, CAV-2, and CPV-2, to be administered in accordance with the recommendations of the American Animal Hospital Association Canine Vaccine Task Force.     

Chronological analysis of canine parvovirus type 2 isolates in Japan

Fifty-five canine parvovirus type 2 (CPV) samples, 12 fecal specimens and 43 cell culture isolates, were examined for their genetic characteristics of VP2 gene. They were collected from the diseased dogs at various districts of Japan during 27 years from 1980 to 2006. A fragment of VP2 gene was analyzed by restriction fragment length polymorphism assay and DNA sequencing. The original antigenic type 2 of CPV (CPV-2) was no longer found in the samples since 1984, and two antigenic variants CPV-2a and CPV-2b replaced CPV-2 as predominant types for about 5 years from 1982. A new genetic variant of prototype CPV-2a with non-synonymous substitution at the VP2 amino acid residue 297 from Ser to Ala was first detected in 1987. New CPV-2b with the same amino acid substitution at position 297 as new CPV-2a was also detected from the samples collected in 1997. Since then new CPV-2b has been the predominant CPV over the field of Japan. Several additional amino acid substitutions were detected in the VP2 gene of some recent CPV strains. Neither CPV-2c(a), CPV-2c(b), nor "Glu-426" of the antigenic variants previously found outside the country was detected in any samples tested. Reactivity of new CPV-2a and 2b variants against antibodies produced by the current vaccine products was determined by a cross hemagglutination-inhibition test. The recent field CPV isolates reacted more efficiently to the antibodies produced in dogs vaccinated with the new CPV-2b vaccine strain than the conventional CPV-2 vaccine strain.